Cariprazine

BreastfeedingGeriatricPediatric
  • TRADE NAME: Vraylar (Forest)
  • INDICATIONS: Schizophrenia; manic or mixed episodes associated with bipolar I disorder
  • CLASS: Antipsychotic
  • HALF-LIFE: 2–4 days

FDA APPROVAL DATE: 09/17/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A4 inducers

PREGNANCY CATEGORY: N/A
Neonatal risk in third trimester exposure

BLACK BOX WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Our database has 51 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 10/11/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top